1. Bempedoic acid and inclisiran for patients with heterozygous familial hypercholesterolemia and for secondary prevention of ASCVD: final policy recommendations Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, March 2, 2021 Subject(s): Cardiovascular Diseases -- prevention & controlCholesterol, LDL -- antagonists & inhibitorsHypercholesterolemia -- drug therapyUnited States
